Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders

Zymeworks acquires struggling Theravance for $929M

Four months after Theravance Biopharma shut down its R&D unit, laid | Four months after Theravance Biopharma shut down its R&D unit, laid off half its staff and signaled it was up for sale, the Dublin-based company has…